Quality Indicators – ESGO Gynae-Oncology Guidelines

Quality Indicators for the surgical treatment of endometrial carcinoma


Based on the ESGO-ESTRO-ESP Endometrial cancer guidelines developed from 2019-2020, 29 structural, process and outcome indicators were defined. They are related to center case olad, training, experience of the surgeon, structured multi-disciplinarity of the team and active participation in clinical research. Two  indicators ar related to the adequate pre-operative invetsigations, 14 to peri-operative standards of care. One indicator is related to molecular markeers for endometrial carcinoma diagnosis and determinants for treatment decisions. Another quality indicator is dedicated to the management of patients after primary surgical treatment and last five indicators highlight the need for a systematic assessment of surgical morbidity and oncologic outcome. An assessment form including a scoring systém was built as a basis for ESGO accreditation of centrs for endometrial cancer surgery.

The article was published in December 2021 and is available here: ESGO Quality Indicators for the surgical treatment of endometrial carcinoma. You can read it HERE.

Name Specialty Affiliation
Nadeem Abu-Rustum Gynaecological Oncologist Memorial Sloan Kettering Cancer Center, New York (USA)
Beyhan Ataseven Gynaecological Oncologist Evangelische kliniken Essen-Mitte, University Hospital Munich (Germany)
David Cibula Gynaecological Oncologist First Faculty of Medicine, General University Hospital of Charles University in Prague (Czech Republic)
Nicole Concin Gynaecological Oncologist (Chair) Innsbruck Medical University (Austria), Evangelische kliniken Essen-Mitte (Germany)
Anna Fagotti Gynaecological Oncologist Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome (Italy)
Christina Fotopoulou Gynaecological Oncologist Imperial College London Faculty of Medicine, London (UK)
Pawel Knapp Gynaecological Oncologist University Oncology Center, Medical University of Bialystok (Poland)
Christian Marth Gynaecological Oncologist Innsbruck Medical University (Austria)
Philippe Morice Gynaecological Oncologist Institut Gustave Roussy, Villejuif, Paris (France)
Jan Persson Gynaecological Oncologist (Chair) Skåne University Hospital, Lund University, Faculty of Medicine, Clinical Sciences, Lund (Sweden)
Denis Querleu Gynaecological Oncologist Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome (Italy), University Hospital Strasbourg (France)
Jalid Sehouli Gynaecological Oncologist Campus Virchow Klinikum, Charite-Universtätsmedizin Berlin, Corporate Member of Freie Universität zu Berlin and Berlin Institute of Health, Berlin (Germany)
Artem Stepanyan Gynaecological Oncologist Nairi Medical Center, Yerevan (Armenia)
Cagatay Taskiran Gynaecological Oncologist Koç University School of Medicine, Ankara, VKV American Hospital, Istanbul (Turkey)
Ignace Vergote Gynaecological Oncologist Leuven Cancer Institute, Catholic University Leuven (Belgium)
Pauline Wimberger Gynaecological Oncologist Department of Gynecology and Obstetrics, Technische Universität Dresden, National Center for Tumour Diseases, Dresden, German Cancer Research Center, Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden,  Medizinische Fakultat Carl Gustav Carus, Dresden, Helmholtz-Zentrum Dresden-Rossendorf (Germany)
Ignacio Zapardiel Gynaecological Oncologist La Paz University Hospital - IdiPAZ, Madrid (Spain)